12-Dec-2025
Globe Newswire (Tue, 25-Nov 7:30 AM ET)
BrainsWay Launches First Clinical Trial of Deep TMS 360 System for Alcohol Use Disorder
Globe Newswire (Mon, 17-Nov 7:30 AM ET)
Globe Newswire (Thu, 13-Nov 6:00 AM ET)
BrainsWay Raises Full-Year Outlook After Reporting 29% Revenue Growth and 137% Jump in Profit
Market Chameleon (Tue, 11-Nov 4:15 AM ET)
BrainsWay Reports Third Quarter 2025 Financial Results and Operational Highlights
Globe Newswire (Tue, 11-Nov 7:30 AM ET)
Globe Newswire (Tue, 4-Nov 8:00 AM ET)
BrainsWay to Report Third Quarter 2025 Financial Results on November 11, 2025
Globe Newswire (Tue, 28-Oct 8:00 AM ET)
BrainsWay Announces Additional Minority-Stake Investments in Leading U.S. Mental Health Providers
Globe Newswire (Mon, 27-Oct 7:30 AM ET)
Business Wire (Tue, 21-Oct 8:28 AM ET)
Globe Newswire (Tue, 16-Sep 8:30 AM ET)
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
Brainsway Ltd. - American Depositary Shares trades on the NASDAQ stock market under the symbol BWAY.
As of December 12, 2025, BWAY stock price declined to $16.97 with 39,699 million shares trading.
BWAY has a beta of 1.21, meaning it tends to be more sensitive to market movements. BWAY has a correlation of 0.20 to the broad based SPY ETF.
BWAY has a market cap of $331.82 million. This is considered a Small Cap stock.
Last quarter Brainsway Ltd. - American Depositary Shares reported $14 million in Revenue and $.04 earnings per share. This beat revenue expectation by $470,850 and missed earnings estimates by -$.03.
In the last 3 years, BWAY traded as high as $18.18 and as low as $1.38.
The top ETF exchange traded funds that BWAY belongs to (by Net Assets): IZRL, APIE.
BWAY has outperformed the market in the last year with a return of +74.4%, while the SPY ETF gained +14.0%. In the last 3 month period, BWAY beat the market returning +7.6%, while SPY returned +4.0%. However, in the most recent 2 weeks BWAY has underperformed the stock market by returning -3.0%, while SPY returned -0.2%.
BWAY support price is $16.80 and resistance is $18.04 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BWAY shares will trade within this expected range on the day.